Patents Assigned to Zalicus Pharmaceuticals, Ltd.
  • N-piperidinyl acetamide derivatives as calcium channel blockers
    Patent number: 9096522
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: August 4, 2015
    Assignee: Zalicus Pharmaceuticals, Ltd.
    Inventors: Hassan Pajouhesh, Ramesh Kaul, Yanbing Ding, Yongbao Zhu, Lingyun Zhang, Nagasree Chakka, Michael Edward Grimwood, Jason Tan, Yuanxi Zhou
  • BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL
    Publication number: 20140187533
    Abstract: The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions.
    Type: Application
    Filed: March 2, 2012
    Publication date: July 3, 2014
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan Pajouhesh, Richard Holland, Lingyun Zhang, Hossein Pajouhesh, Jason Lamontagne, Brendan Whelan
  • BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20140113898
    Abstract: The invention relates to bisarylsulfone and dialkylarylsulfone compounds (e.g., compounds according to any of Formulas (I)-(IX) or compounds (1)-(227) of Tables 4 and 5) useful in treating conditions associated with calcium channel function, and particularly conditions associated with N-type calcium channel activity. The invention also relates to pharmaceutical compositions that include these bisarylsulfone compounds, as well methods for the treatment of conditions such as cardiovascular disease, epilepsy, cancer and pain.
    Type: Application
    Filed: November 4, 2011
    Publication date: April 24, 2014
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan A. Pajouhesh, Richard Holland, Yuanxi Zhou, Yongbao Zhu, Michael Edward Grimwood, Navjot Chahal
  • Oxopiperazine derivatives for the treatment of pain and epilepsy
    Patent number: 8629149
    Abstract: Compounds of formula (I) which are useful in ameliorating conditions characterized by unwanted sodium and/or calcium channel actrvrh, particularly Nav 1, 7, Nav 1, 8, or Cav 3, 2 channel activity are disclosed. More specifically, compounds for use in the treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's disease, depression, schizophrenia, psychosis, and tinnitus are disclosed.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: January 14, 2014
    Assignee: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan Pajouhesh, Yanbing Ding
  • N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20140011996
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Application
    Filed: August 29, 2013
    Publication date: January 9, 2014
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan Pajouhesh, Ramesh Kaul, Yanbing Ding, Yongbao Zhu, Lingyun Zhang, Nagasree Chakka, MIchael Edward Grimwood, Jason Tan, Yuanxi Zhou
  • Solid dispersion formulations and methods of use thereof
    Patent number: 8591944
    Abstract: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: November 26, 2013
    Assignee: Zalicus Pharmaceuticals Ltd.
    Inventors: Mahesh V. Padval, Jeff T. Gautschi, Daniel T. Smithey, Marshall D. Crew, Abizer Harianawala
  • N-piperidinyl acetamide derivatives as calcium channel blockers
    Patent number: 8569344
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: October 29, 2013
    Assignee: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan Pajouhesh, Ramesh Kaul, Yanbing Ding, Yongbao Zhu, Lingyun Zhang, Nagasree Chakka, Mike Grimwood, Jason Tan, Yuanxi Zhou
  • SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20130231350
    Abstract: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.
    Type: Application
    Filed: April 1, 2013
    Publication date: September 5, 2013
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Mahesh V. Padval, Jeff T. Gautschi, Daniel T. Smithey, Marshall D. Crew, Abizer Harianawala
  • SELF-EMULSIFYING FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20130184290
    Abstract: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more self-emulsifying carriers.
    Type: Application
    Filed: October 26, 2012
    Publication date: July 18, 2013
    Applicants: CAPSUGEL, Inc., Zalicus Pharmaceuticals Ltd.
    Inventors: Zalicus Pharmaceuticals Ltd., CAPSUGEL, Inc.
  • Solid dispersion formulations and methods of use thereof
    Patent number: 8409560
    Abstract: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: April 2, 2013
    Assignee: Zalicus Pharmaceuticals Ltd.
    Inventors: Mahesh V. Padval, Jeff T. Gautschi, Daniel T. Smithey, Marshall D. Crew, Abizer Harianawala
  • N-piperidinyl acetamide derivatives as calcium channel blockers
    Patent number: 8377968
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: February 19, 2013
    Assignee: Zalicus Pharmaceuticals, Ltd.
    Inventors: Hassan Pajouhesh, Ramesh Kaul, Yanbing Ding, Yongbao Zhu, Lingyun Zhang, Nagasree Chakka, Mike Grimwood, Jason Tan, Yuanxi Zhou
  • SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20130035345
    Abstract: The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.
    Type: Application
    Filed: March 7, 2012
    Publication date: February 7, 2013
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Mahesh V. Padval, Jeff T. Gautschi, Daniel T. Smithey, Marshall D. Crew, Abizer Harianawala
  • Method for increasing the bioavailability of benzhydryl piperazine containing compounds
    Patent number: 8362021
    Abstract: A method of increasing the bioavailability of a compound of formula 1 by orally administering to a patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, with food:
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: January 29, 2013
    Assignee: Zalicus Pharmaceuticals Ltd.
    Inventors: Terrance P. Snutch, Dennis M. Fisher
  • ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20120245137
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I).
    Type: Application
    Filed: September 17, 2010
    Publication date: September 27, 2012
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan A. Pajouhesh, Robert Galemmo, JR., Richard Holland, Yuanxi Zhou, Yongbao Zhu, Eric Simonson, Navjot Chahal, Mike Grimwood
  • OXOPIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY
    Publication number: 20120220605
    Abstract: Compounds of formula (I) which are useful in ameliorating conditions characterized by unwanted sodium and/or calcium channel actrvrh, particularly Nav1.7, Nav 1.8, or Cav 3.2 channel activity are disclosed. More specifically, compounds for use in the treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's disease, depression, schizophrenia, psychosis, and tinnitus are disclosed.
    Type: Application
    Filed: September 3, 2010
    Publication date: August 30, 2012
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan Pajouhesh, Yanbing Ding
  • SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY
    Publication number: 20120220603
    Abstract: Compounds of formula (I) which are useful in ameliorating conditions characterized by unwanted sodium and/or calcium channel activity, particularly unwanted NaV 1.7, NaV 1.8, or CaV 3.2 channel activity are disclosed. Specifically, a series of compounds containing piperidine or piperazine linked through an amide, isoxazole or similar linker to an aryl ring are described and are shown to be useful for the treatment of pain or epilepsy. A is selected from Formulae (i) or (ii).
    Type: Application
    Filed: September 3, 2010
    Publication date: August 30, 2012
    Applicant: ZALICUS PHARMACEUTICALS LTD.
    Inventors: Hassan Pajouhesh, Mike Grimwood, Yongbao Zhu, Yanbing Ding, Richard Holland
  • SELECTIVE CALCIUM CHANNEL MODULATORS
    Publication number: 20120220564
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed using a series of compounds containing N-acylated cyclic amines linked to an a?l ring as shown in formula (I).
    Type: Application
    Filed: September 17, 2010
    Publication date: August 30, 2012
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan Pajouhesh, Yongbao Zhu, Yuanxi Zhou, Michael E. Grimwood, Eric Simonson
  • Bicyclic pyrimidine derivatives as calcium channel blockers
    Patent number: 8133998
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing thienopyrimidine or oxoquinazoline derivatives are disclosed of the general formula (1) or formula (2) where X is a linker and Y is an aromatic moiety or N(R5)(R6).
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: March 13, 2012
    Assignee: Zalicus Pharmaceuticals, Ltd.
    Inventors: Hassan Pajouhesh, Hossein Pajouhesh, Yanbing Ding, Jason Tan, Mike Grimwood, Francesco Belardetti, Ramesh Kaul, Richard Holland, Navjot Chahal